Overview
Pathways to Transfusion Independence & Reduced Health Complications: Advances for Lower-Risk MDS
Click the"View Activity" button to view this activity.
View ActivityCME/CE is no longer available for this activity
In this dynamic case challenge format, expert faculty work through two patient cases and offer supporting data and practical experience to establish optimal recognition, diagnostic, and treatment practices, and discuss opportunities for shared decision making with patients. Learners are questioned about how they would proceed at different clinical decision points, and faculty commentaries offer recommendations and evidence for next steps. This activity outlines ways to identify and diagnose patients with nonspecific symptoms, differentiate between risk levels, and choose appropriate therapeutic options.
This activity is intended for hematologists, pathologists, hematopathologists, medical oncologists, and other clinicians who treat patients with myelodysplastic syndromes (MDS).
Patients with MDS are affected by anemia and anemia-related symptoms, and while two-thirds of patients with MDS have lower-risk disease, there has been no clear standard of care. Because prognostic scoring systems are used to help identify the risk of MDS progression to AML and support optimal treatment recommendations, hematologists/oncologists and pathologists must have a shared understanding about the goals of treatment and how improving the diagnosis, risk assessment, and treatment for patients with low-risk disease can lead to better long-term outcomes. To improve management practices across the spectrum of care, this activity employs the use of simulated cases presented in the context of two pathways—one for hematologists/oncologists and one for pathologists—to explore the key considerations and decision-making steps reflective of the scope of different clinical practices.
Upon completion of this activity, participants will be able to:
• Explain the criteria for MDS diagnosis as well as risk stratification methods
• Describe the common presentation of MDS with ring sideroblasts
• Integrate a well-coordinated interprofessional team approach to provide effective care to patients with MDS and ring sideroblasts
• Analyze recent clinical trial data regarding the efficacy of new and emerging agents that are used for the treatment of lower-risk MDS
• Integrate new therapies into treatment plans for patients with lower-risk MDS and concomitant anemia
• Explain the criteria for MDS diagnosis as well as risk stratification methods
• Describe the common presentation of MDS with ring sideroblasts
• Integrate a well-coordinated interprofessional team approach to provide effective care to patients with MDS and ring sideroblasts
• Analyze recent clinical trial data regarding the efficacy of new and emerging agents that are used for the treatment of lower-risk MDS
• Integrate new therapies into treatment plans for patients with lower-risk MDS and concomitant anemia
This activity is sponsored by the Academy for Continued Healthcare Learning.
This activity is supported by an educational grant from Bristol-Myers Squibb.
Daniel A. Pollyea, MD, MS
Associate Professor, Medicine-Hematology
University of Colorado School of Medicine
Aurora, CO
Associate Professor, Medicine-Hematology
University of Colorado School of Medicine
Aurora, CO
Jamile Shammo, MD, FASCP, FACP
Professor of Medicine and Pathology
Division of Hematology, Oncology, and Stem Cell Transplant
Rush University Medical Center
Chicago, IL
The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been mitigated prior to this activity.
The following financial relationships have been provided:
Daniel A. Pollyea, MD, MS
Advisory/Review Panel: Abbvie, Amgen, Aprea, Arcellex, Astellas, BeiGene, BerGenBio, Celgene, Foghorn, Genentech, Jazz, Karyopharm, Novartis, Syndax, Syros, Takeda
Consultant (occasional): Abbvie, Bristol Myers Squibb, Genentech, Gilead, Karyopharm, Kiadis, Syros
Grant/Research Support: Abbvie, Bristol Myers Squibb, Karyopharm
Jamile Shammo, MD, FASCP, FACP
Board Member: MJH Life Sciences
Consultant (occasional): Alexion-Astra Zeneca, Bristol Myers Squibb, Incyte, Sanofi
Consultant (retained): MJH Life Sciences
Grant/Research Support: Alexion-Astra Zeneca, Bristol Myers Squibb, Incyte, Abbvie, CTI, Kartos
Speakers Bureau: Alexion-Astra Zeneca, Bristol Myers Squibb, Incyte
Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: Lenalidomide is not FDA-approved for lower-risk MDS not associated with a deletion 5q abnormality; luspatercept is not FDA-approved for lower-risk MDS without ring sideroblasts; decitabine is not FDA-approved for IPSS very-low- or low-risk MDS; epoetin alfa and darbepoetin alfa are not FDA-approved for the treatment of anemia due to MDS; antithymocyte globulin (ATG) and ATG-based combination therapies including cyclosporine with or without eltrombopag, are not FDA-approved for the treatment of MDS
ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.
This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This CME/CE activity might describe the off-label, investigational, or experimental use of medications that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.
This activity will take approximately 60 minutes to complete. To receive credit, participants are required to complete the pretest, view the online activity and complete the posttest and evaluation. To receive credit, 60% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.
The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC point in the American Board of Pathology’s Maintenance of Certification (MOC) program. This activity offers the following types of credit: Lifelong Learning (Part II).
By providing your ABPath Diplomate number, you consent to have ACHL and/or our educational partners submit your participation in this activity to the ABPath through the ACCME PARS system.
MOC points will be submitted the first of every month.
